Understanding aberrant white matter development in schizophrenia: an avenue for therapy?
Understanding aberrant white matter development in schizophrenia: an avenue for therapy?
复制标题
DOI：
10.1586/ern.11.76
复制
发表时间：
2011-07
影响因子：
4.3
通讯作者：
M. Walterfang;D. Velakoulis;T. Whitford;C. Pantelis
中科院分区：
文献类型：
--
作者：
M. Walterfang;D. Velakoulis;T. Whitford;C. Pantelis
尽管历史上灰质变化一直是精神分裂症的神经病理学和神经放射学研究的焦点，但近年来越来越多的研究涉及白质结构及其组成成分（轴突、髓鞘和支持少突胶质细胞）。本文总结了这方面的文献，检查了精神分裂症白质病理的神经病理学、神经遗传学和神经放射学证据。然后，我们研究了抗精神病药物在这些研究中可能发挥的作用，检查了它在检查神经元密度和脑容量的研究中作为潜在混杂因素的作用，以及这些药物通过对少突胶质细胞的作用促进髓鞘形成的可能作用。最后，讨论了潜在的新疗法的作用。
Although historically gray matter changes have been the focus of neuropathological and neuroradiological studies in schizophrenia, in recent years an increasing body of research has implicated white matter structures and its constituent components (axons, their myelin sheaths and supporting oligodendrocytes). This article summarizes this body of literature, examining neuropathological, neurogenetic and neuroradiological evidence for white matter pathology in schizophrenia. We then look at the possible role that antipsychotic medication may play in these studies, examining both its role as a potential confounder in studies examining neuronal density and brain volume, but also the possible role that these medications may play in promoting myelination through their effects on oligodendrocytes. Finally, the role of potential novel therapies is discussed.